Starfleet Innotech, Inc. (OTCMKTS:SFIO) Partners with European Biological Medicine to Set up New Medical Tourism Ventures in the Asia-Pacific
Starfleet Innotech, Inc. (OTCMKTS:SFIO) and European Biological Medicine, Inc. (EBMI) have signed an official memorandum of understanding (MOA). The purpose is to jointly develop and operate a first-rate integrative care facility in Palawan, Philippines.
Starfleet Innotech Signs Binding Agreement with European Wellness to Pioneer New Medical Tourism Ventures in the Asia-Pacific
EBMI is a subsidiary of the European Wellness Biomedical Group, well-known for its innovative developments in precursor stem cell therapeutics, immunomodulation, biological peptides, and biological regenerative medicine. Members of the Starfleet executive team have met with EBMI leadership in Malaysia to finalize this agreement, along with plans for a groundbreaking ceremony and site visit in Palawan in the second quarter of this year.
This collaboration of EBMI and Starfleet marks the beginning of a new chapter in proactive, integrative care in the Philippines. A cutting-edge wellness center for integrative medicine is to be placed within Starfleet’s $50-M eco-luxury community project in world-renowned Puerto Princesa, Palawan, a project under wellness-oriented real estate firm Moraya.
Moraya’s Buenavista project offers a warm and inviting environment for short and long-term visitors, along with long-term residents, so they can reconnect with nature. The tropical design is reminiscent of Filipino hospitality, featuring the nation’s iconic pitched roofs, woven textures, and natural shade elements.